This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.
Identification of Camphor Derivatives as Novel M2 Ion Channel Inhibitors of Influenza A Virus

Xin Zhao,* Zhen-Wei Zhang,‡ Wei Cui,‡ Shengwei Chen,‡ Yang Zhou,‡ Jianghong Dong,‡ Yanling Jie,‡ Junting Wan,‡ Yong Xu* and Wenhui Hu*‡

Amantadine derivatives have been the only drugs marketed as M2 inhibitors of influenza A for decades. The identification of pinanamine as a novel M2 inhibitor suggests that M2 ion channels can accommodate more types of hydrophobic scaffolds. Herein, we further investigated M2 ion channels and identified camphor derivatives as new types of M2 inhibitors. Compound 18 was found to be more potent than amantadine against wild-type influenza virus. The molecular docking revealed that compound 18 occupies more space in the M2 ion channel than amantadine and thus exhibited enhanced activity.

Influenza A viruses (IAVs) are easily transmitted and adversely affect the respiratory system, therefore they are a severe threat to human health. Every year, influenza epidemics result in the deaths of individuals and economic losses. There have been three influenza pandemics over the last century with high mortality rates for humans.1 In recent years, new strains of IAV have emerged, such as the highly pathogenic avian influenza (HPAI) H5N1 strain (avian flu) and H1N1 influenza (swine flu).2 In 2013, there was an outbreak of a new H7N9 avian influenza virus in China.3 These sudden and unpredictable outbreaks pose a severe threat to the health of animals and humans. New and efficient therapeutics to combat IAV infections are urgently needed. Currently, there are two classes of antiviral drugs for treating human IAV infections: M2 ion channel inhibitors (amantadine and rimantadine, Fig. 1), and neuraminidase inhibitors (oseltamivir and zanamivir).4 However, some strains of IAV have become resistant to existing drugs, in particular the M2 ion channel inhibitors, which have been limited to clinical use by the FDA.5 There are also some issues with neuraminidase inhibitors: zanamivir needs to be administered by inhalation, while there have been an increasing number of reports regarding resistance to orally bioavailable oseltamivir.6,7 Alternative antivirals should be developed to deal with this situation.

Amantadine has been successfully used for over three decades to block the M2 protein of IAV. M2 is a proton-selective ion channel protein in the viral envelope of IAV comprising 97 amino acids, and plays an essential role in viral replication.8–10 The ion channel is a homotetramer consisting of four M2 units; mutations in the M2 channel lead to amantadine resistance.11–15 Side effects on the central nervous system (CNS) are another drawback of M2 ion channel inhibitors, thereby limiting their use.16–18 All known M2 ion channel inhibitors contain a hydrophobic scaffold linked to a polar head group. Inhibitors containing the adamantane-based scaffold, such as compounds 1–3 (Fig. 1), target M2 proteins containing wild-type (WT), L26F, V27A or S31N mutations.19–22 Some compounds carrying large cage-based scaffolds inhibit WT M2 and/or V27A mutants;23–26 however, A/M2-V27A inhibitor 4 (Fig. 1) exhibits some cytotoxicity.25 Investigating novel non-adamantane-based M2 inhibitors is of interest in the treatment of IAV infections.
Compound 5 (Fig. 1), known as (1R,2R,3R,5S)-3-pinanamine (Pinanamine), was found to be more active than amantadine with respect to WT A/M2 inhibition.27 Linking a secondary amine to a methylimidazole group on the pinanamine scaffold (Compound 5, Fig. 2) could further increase the inhibition of A/M2 channel activity. For the S31N mutant, this resulted in improved inhibition compared with that by amantadine.28 Encouraged by this promising result, we considered using strategies of classical pharmacophore modification (green shade, Fig. 2) and scaffold extending and transition approaches for optimization of novel M2 inhibitors (blue shade, Fig. 2). On one hand, by pharmacophore modification, several more potent compounds inhibiting mutant amantadine-resistance strains have been discovered, these results led us to consider to explore the druggability of these small-molecule towards discovering new candidates for anti-influenza A therapy. On the other hand, as an initial step of this research pipeline, it is important to explore the hydrophobic scaffold of pinanamine and investigate their activity targeting WT-M2 to identify dominant scaffold.

Bicyclo [2.2.1] heptanes (compound 21)29 and its analogues30, borneol amines, and its derivatives based on the camphor scaffold were reported had anti-influenza activity.31-33 In this study, we extended the hydrophobic scaffold of pinanamine and borneol amines with camphor scaffold and designed some novel scaffold amino compounds which inhibit the WT M2 ion channel of influenza A virus. Among them, the pinanamine analogue 18, methyl-substituted camphor ethylamine, exhibited potent activity against WT influenza A virus. The docking computations demonstrate that 18 can bind within the channel pore and its amino group directed toward the C-terminal. And 18 was found to be able to occupy larger space in M2 channel than amantadine, this may enhance its activity. Design and Synthesis of New M2 Inhibitors. To explore the impact of pinanamine analogs, we extended its hydrophobic framework, along with the similar scaffolds camphor and fenchone. Synthetic routes are shown in Schemes 1 and 2. Commercially available (1R,2R,3R,5S)-(-)-isopinocamphor was oxidized by pyridinium dichromate (PDC) in CH₂Cl₂ to give compound 6.34 Reductive cyanation of 6 with tosylmethylisocyanide (TosMIC) gave nitrile 7 with high stereoselectivity,35,36 which was followed by reduction with LiAlH₄ to obtain methylene-inserted pinanamine. This was treated with HCl/CH₂OH to give hydrochloride 8 with a 44 % yield over three steps. Compound 7 could be hydrolyzed to acid 9,37 which was treated with CH₃Li to produce methyl ketone 10.20 Oxime 11 was prepared by reacting 10 with hydroxylamine; this was followed by LiAlH₄ reduction and salification, and 11 was converted to mixture of two isomers of methyl-substituted ethyl amine 12 with a 24.3 % overall yield. To extend the camphor and fenchone scaffold, the same reactions were used and gave the mixture of two isomers of compounds 18 and 20 respectively, except for the cyanation of (+)-camphor, where we acquired a higher yield by heating to 45°C.

Pharmacological Activity. We obtained 50% inhibitory concentration (IC₅₀) values using viral inhibition assays (Table 1). Pinanamine (5) is a potent inhibitor of the WT M2 ion channel. We extended the length of 5 by inserting a methylene; corresponding compound 8 led to a marked loss of potency (IC₅₀ = 2.47 vs. 0.12 μM). The methyl-substituted analog of 8,
compound 12, had a similar structure compared with rimantadine but little increase in activity. Rimantadine showed an obvious improvement in antiviral activity compared with amantadine. Based on our findings, we believe it would be disadvantageous to extend the length of the amino and pinanak framework linker.

Examination of 2-amino norbornane hydrochloride (21) and its exo isomer (22) showed a scaffold with a bridge-ring similar to 5, but different from 5 as it had four- and six-member rings with two five-member rings available (Fig. 3).39 The potencies of 21 and 22 were significantly decreased, but allowed us to conclude that this kind of borneol scaffold should be used. Adding three methyl groups on bridge carbon atoms yielded a much more potent compound, bornylamine (23), with an IC_{50} of 0.49 µM. Bornylamine inhibited AIV virus to a comparable degree as amantadine; moving the two methyl groups of the bridge to the β carbon atom (compound 20) led to a marked loss of activity. This indicates that the two methyl groups of the bridge are necessary. Encouraged by potential compound 23, we extended the linker of the scaffold and amino group. Compound 14 was a little more potent with an IC_{50} of 0.29 µM. Its potency was further enhanced by adding a methyl group on the linker, producing the methyl-substituted camphor ethylamine 18 with an IC_{50} of 0.10 µM. Compound 18 was five-fold more active than amantadine and as potent as pinanamine.

All compounds were also tested for their inhibition of amantadine-resistant strain (A/WSN/33, M2-S31N), but unfortunately, no effects were shown.

### Table 1 Inhibition efficiency of compounds on IAV

<table>
<thead>
<tr>
<th>Compound</th>
<th>A/M2 WT IC_{50} (µM)</th>
<th>Compound</th>
<th>A/M2 WT IC_{50} (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>2.47 ± 0.54</td>
<td>21</td>
<td>17.40 ± 4.36</td>
</tr>
<tr>
<td>12</td>
<td>1.93 ± 0.62</td>
<td>22</td>
<td>12.40 ± 2.01</td>
</tr>
<tr>
<td>14</td>
<td>0.29 ± 0.10</td>
<td>23</td>
<td>0.49 ± 0.16</td>
</tr>
<tr>
<td>18</td>
<td>0.10 ± 0.05</td>
<td>5</td>
<td>0.12 ± 0.02</td>
</tr>
<tr>
<td>20</td>
<td>15.70 ± 0.30</td>
<td>amantadine</td>
<td>0.50 ± 0.16</td>
</tr>
</tbody>
</table>

*a A/M2-WT virus (A/Hong Kong/68, strain H3N2)

*IC_{50} is presented as mean ± SD.

**Plaque Reduction Assays.** The effectiveness of compound 18 against IAV was confirmed by plaque reduction assays. The size and number of plaques for the WT influenza virus (A/Hong Kong/68) were significantly reduced by 18 at 1 and 0.2 µM (Fig. 5).

**Molecular Docking.** We conducted molecular docking studies to investigate the binding of 18 to the A/M2 WT ion channel. SSNMR and X-ray studies of amantadine binding to the M2 ion channel showed that amantadine binds to residues 27–31 of the transmembrane (TM) domain, and its amino group was oriented towards the C-terminus.40, 41 A molecular docking simulation showed that the tilt angle of amantadine and the deviation from the Ser31 Cα plane was clearly different from those determined by SSNMR.23 Using docking computations, we found that the docking conformation of amantadine agreed with the molecular docking simulation performed by Duque23 (Fig. S1A), with a similar conformation of compound 18 identified (Fig. S1B and C). A stick model showed that a C=O…H hydrogen bond might form between the protonated amino and carbonyl group of Ala30 (Fig. 6A), and 18 had a closer distance (2.5 Å) to Ala30 of the M2 channel than that of amantadine (3.4 Å). This might enhance the strength of the hydrogen bond from 18 (Fig. 6B). A space-filling model indicated that 18 could occupy more room in the M2 channel than amantadine, which might enhance its activity (Fig. 7).

**Fig. 4** Inhibition of M2 WT ion channel conductivity by various compounds as determined by patch clamp assays.

**Fig. 5** Plaque reduction assays for compound 18 on WT influenza virus (A/Hong Kong/68).

**Fig. 6** Inhibition of M2 WT ion channel conductivity by various compounds as determined by patch clamp assays.

**Fig. 7** Plaque reduction assays for compound 18 on WT influenza virus (A/Hong Kong/68).

**Fig. 3** Structures of some borneol amines.

**Patch clamp assays.** To test the inhibitory properties of compounds targeting the M2 ion channel, patch clamp assays were applied to 293Trex cells with WT A/M2. All inhibitors were tested at 100 µM and the inhibitory activity (%) of each compound as found (Fig. 4). These results were consistent with those from the viral inhibition assays.
could be developed as backup scaffolds for a new generation of M2 inhibitors.

Acknowledgements

This research was supported by funding from the State Key Laboratory of Respiratory Disease, the National Natural Science Fund of China (Grant No.81302648) and the Guangzhou Science and Technology Plan (Grant No. 20130000052). We thank Yi-Xia Ling for assistance in obtaining HRMS data.

Notes and references

* Corresponding authors
(W. Hu) E-mail: hu_wenhu@gibh.ac.cn; Tel: +86-20-32015211
(Y. Xu) E-mail: xu_yong@gibh.ac.cn.
(X. Zhao) E-mail: zhao_xin@gibh.ac.cn.

† State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, People’s Republic of China.

‡ Electronic Supplementary Information (ESI) available: Biological experiments, general method of chemistry, synthesis of target compounds, intermediate products, and their characterization. Docking conformation of amantadine and compound 18. See DOI: 10.1039/c000000x/

Evaluation of cytotoxicity. All compounds were tested for cytotoxicity in MDCK cells. The minimum cytotoxic concentration (MCC) of these compounds was higher than 300 µM.

Conclusions

In order to generate new type of M2 inhibitors other than amantadine derivatives, more hydrophobic scaffolds have been investigated in this study. Camphor derivatives were identified to be a new class of M2 inhibitors with moderate activity. Among of them, compound 18 was found to be 5 times more active than Amantadine. The molecular docking revealed that compound 18 occupies more space in the M2 channel than amantadine, and thus exhibits enhanced activity. We conclude that 18 represents a new series of anti-influenza virus drugs and could be developed as backup scaffolds for a new generation of M2 inhibitors.


